Wyeth Pinning Near-Term Growth Hopes On Enbrel, Prevnar
This article was originally published in The Pink Sheet Daily
Executive Summary
The rheumatoid arthritis agent and pneumococcal conjugate vaccine are less sensitive to pricing pressure, giving them better growth prospects, the company says. Wyeth expects to file six "major" NDAs in next two years as it looks to new products to off-set pricing pressure over the long term.
You may also be interested in...
Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November
FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.
Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November
FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.
Protonix Average Price Increases By 8% As Wyeth Cuts Medicaid Contracts
Focus on key managed care accounts and elimination of some state contracts has resulted in an 8% weighted average price increase compared to first quarter 2004. Protonix shows 10% total prescription growth, but posts flat sales due to 9% inventory workdown.